Recent Price Movement and Market Comparison
The stock has been on a consistent slide, losing 6.54% over the past week compared to a modest 0.55% decline in the Sensex. Over the last month, the stock’s fall has been even more pronounced at 13.04%, while the Sensex gained 1.74%. Year-to-date, Piramal Pharma’s shares have plummeted nearly 35%, starkly contrasting with the Sensex’s 8.35% rise. This trend extends over the last year as well, with the stock down 32.34% against the Sensex’s 3.87% gain. Even over three years, the stock’s 34.45% return trails the Sensex’s 36.16%, signalling persistent underperformance.
On 09-Dec, the stock touched an intraday low of ₹170.4, marking a fresh 52-week low. It has now declined for five consecutive days, underperforming its sector by 0.79% on the day. Technical indicators also point to weakness, with the share price trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Despite this, investor participation has risen, with delivery volumes on 08-Dec increasing by 36.66% compared to the five-day average, suggesting heightened trading activity amid the decline.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Fundamental Challenges Weighing on the Stock
While Piramal Pharma has demonstrated healthy long-term operating profit growth at an annual rate of 23.29%, this has not translated into strong overall financial health or investor returns. The company’s return on capital employed (ROCE) stands at a modest 2.7%, and it trades at a discount relative to peers based on enterprise value to capital employed of 2.2. However, these positives are overshadowed by significant profit declines and weak recent earnings.
Over the past year, the company’s profits have plunged by 158.7%, a dramatic deterioration that has contributed to the stock’s 32.34% negative return in the same period. The September 2025 quarterly results were particularly disappointing, with profit before tax excluding other income falling 340% to a loss of ₹111.78 crores. Net profit after tax plunged 613.2% to a loss of ₹99.22 crores, while net sales declined 10.5% to ₹2,043.72 crores compared to the previous four-quarter average. These figures highlight severe near-term operational challenges.
Debt Burden and Profitability Concerns
The company’s ability to service its debt is a major concern, with a high Debt to EBITDA ratio of 3.83 times indicating significant leverage. This level of indebtedness strains financial flexibility and raises risks amid weak profitability. The average return on equity (ROE) is a mere 0.32%, signalling very low profitability relative to shareholders’ funds. Furthermore, net sales growth over the last five years has been modest at an annual rate of 9.15%, reflecting limited top-line expansion.
Institutional investors hold a substantial 45.17% stake in Piramal Pharma, suggesting that well-resourced market participants are closely monitoring the company’s fundamentals. Despite this, the stock’s sustained underperformance relative to the BSE500 index over the last three years, one year, and three months underscores persistent investor scepticism.
Is Piramal Pharma your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Outlook and Investor Considerations
The combination of weak recent earnings, high leverage, and sustained underperformance relative to market benchmarks explains the ongoing decline in Piramal Pharma’s share price. Despite some long-term operating profit growth and a valuation discount, the company’s poor debt servicing capacity and sharply falling profits have eroded investor confidence. The stock’s technical weakness, including trading below all major moving averages and hitting new lows, further dampens near-term prospects.
Investors should carefully weigh these challenges against the company’s fundamentals and consider alternative opportunities within the pharmaceutical sector and broader market. The rising delivery volumes amid the decline may indicate increased trading interest, but the prevailing financial headwinds suggest caution is warranted.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
